as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,356.6
Change
-3.7 (-0.27%)
Open
₹1,361.1
Prev. Close
₹1,360.3
Day High
₹1,388.0
Day Low
₹1,338.0
Volume Analysis
Traded
64,955
Delivered
38,188
Delivery %
58.79%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (2)
- •Promoter holding is falling
- •Below-average fundamentals quality score (49/100)
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,433.74 | ₹1,410.87 | ₹1,383.74 | ₹1,360.87 | ₹1,333.74 | ₹1,310.87 | ₹1,283.74 |
| Fibonacci | ₹1,410.87 | ₹1,391.77 | ₹1,379.97 | ₹1,360.87 | ₹1,341.77 | ₹1,329.97 | ₹1,310.87 |
| Camarilla | ₹1,370.35 | ₹1,365.77 | ₹1,361.18 | ₹1,360.87 | ₹1,352.02 | ₹1,347.43 | ₹1,342.85 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
+0.62%
1 Month
-8.13%
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹275.82
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
13.45%
Net margin 5.88% × asset turnover 0.99x × equity multiplier 2.31x
Company Overview
Sector
Healthcare
Market Cap
₹2,305 Cr
P/E (TTM)
52.6
ROE
15.6%
Book Value
₹170.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.
TopFund Analysis
Fredun Pharmaceuticals L scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Momentum (83/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling; below-average fundamentals quality score (49/100). FII holding has been rising.
TopFund Score — Fundamentals Quality
49/100 — WeakData confidence: 74/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Liquidity
From Screener.in
- +Debtor days have improved from 97.8 to 53.2 days.
- −Stock is trading at 8.22 times its book value
- −Promoter holding has decreased over last 3 years: -5.05%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Fredun allotted 3,61,599 equity shares on 22 Sept 2026 after 1,20,533 warrants conversion.
Fredun Pharmaceuticals acquires 26% stake in Goodman Vetcare, targeting expansion to ~₹100 crore revenue by FY31.
Fredun Pharmaceuticals allotted 2,71,200 equity shares on 16 Sept 2026 after 90,400 warrant conversions.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 0 | 167 | 120 | 145 | 161 | 213 | 228 |
| Expenses + | 0 | 150 | 103 | 123 | 135 | 184 | 196 |
| Operating Profit | 0 | 17 | 17 | 22 | 26 | 29 | 33 |
| OPM % | — | 10.0% | 14.0% | 15.0% | 16.0% | 14.0% | 14.0% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 8 | 7 | 8 | 11 | 14 | 9 |
| Depreciation | 0 | 2 | 1 | 2 | 2 | 3 | 4 |
| Profit before tax | 0 | 7 | 9 | 13 | 14 | 11 | 21 |
| Tax % | — | 17.0% | 25.0% | 26.0% | 25.0% | 4.0% | 36.0% |
| Net Profit + | 0 | 6 | 7 | 9 | 10 | 11 | 13 |
| EPS in Rs | 0 | 4 | 5 | 7 | 7 | 7 | 8 |
| Raw PDF | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| Sales + | 454 | 635 | 748 |
| Expenses + | 401 | 545 | 637 |
| Operating Profit | 52 | 91 | 110 |
| OPM % | 12.0% | 14.0% | 15.0% |
| Other Income + | 2 | 4 | 0 |
| Interest | 22 | 39 | 41 |
| Depreciation | 5 | 8 | 10 |
| Profit before tax | 27 | 47 | 59 |
| Tax % | 28.0% | 31.0% | — |
| Net Profit + | 20 | 33 | 44 |
| EPS in Rs | 14 | 20 | 28 |
| Dividend Payout % | 2.0% | 1.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Reserves | 137 | 273 |
| Borrowings + | 167 | 222 |
| Other Liabilities + | 179 | 142 |
| Total Liabilities | 487 | 642 |
| Fixed Assets + | 53 | 118 |
| CWIP | 0 | 0 |
| Investments | 2 | 2 |
| Other Assets + | 433 | 522 |
| Total Assets | 487 | 642 |
| Equity Capital | 5 | 5 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity + | -17 | 12 |
| Cash from Investing Activity + | -6 | -74 |
| Cash from Financing Activity + | 27 | 121 |
| Net Cash Flow | 4 | 60 |
| CFO/OP | -32 | 13 |
| Free Cash Flow | -23 | -62 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 49.24% | 49.24% | 49.23% | 49.47% | 49.47% | 49.47% | 49.49% | 49.46% | 53.0% | 51.94% | 51.45% | 51.43% |
| Promoters | 49.16% | 49.17% | 49.17% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 43.06% | 44.17% | 44.57% | 44.57% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.01% | 0.46% | 1.06% | 1.06% | 1.06% |
| DII | 1.6% | 1.6% | 1.6% | 1.59% | 1.59% | 1.59% | 1.59% | 1.61% | 3.48% | 2.83% | 2.94% | 2.94% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Fredun Pharmaceuticals L (this stock) | 2,305 | 52.6 | 8.2 | 15.6% |
| Indoco Remedies Ltd. | 2,306 | — | 2.45 | -9.36% |
| Panacea Biotec Ltd | 2,282 | — | 2.74 | -2.42% |
| Windlas Biotech Limited | 2,275 | 34.2 | 4.01 | 12.2% |
| Venus Remedies Limited | 2,230 | 19.2 | 3.36 | 16.8% |
| Sai Parenterals Limited | 2,226 | 107.0 | — | 4.88% |
| Beta Drugs Limited | 2,400 | 52.6 | 8.98 | 18.8% |
Which Mutual Funds Hold Fredun Pharmaceuticals L?
Frequently Asked Questions about Fredun Pharmaceuticals L
Fredun Pharmaceuticals L (FREDUN) closed at ₹1,356.6 on NSE on 25 September 2026, down 3.7 (0.27%) from the previous close.
Fredun Pharmaceuticals L trades on the NSE (National Stock Exchange of India) under the symbol FREDUN.
Fredun Pharmaceuticals L has a trailing twelve-month P/E (price-to-earnings) ratio of 52.6.
Fredun Pharmaceuticals L has a dividend yield of 0.02%.
Fredun Pharmaceuticals L's 52-week high is ₹1,600.0 and its 52-week low is ₹404.0.
Fredun Pharmaceuticals L has a market capitalisation of ₹2,305 crore.
Fredun Pharmaceuticals L has a TopFund Quality Score of 49/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Fredun Pharmaceuticals L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.